1,2,3 In recent years, emerging evidence from preclinical and clinical studies has suggested that new immunological mechanisms are involved in all stages of ALD, including immune response initiation, inflammatory reactions, and completed/unresolved repair
doi: 10.3389/fphar.2014.00173 Received 18 April 2014 Accepted 04 July 2014 Published 22 July 2014 Volume 5 - 2014 Edited by Paolo Arosio, University of Brescia, Italy Reviewed by Constantin Ion Mircioiu, Carol Davila University of Medicine and Pharmacy, Romania
Arvaniti, M
Reported side effects The side effects reported in trials and research protocols tend to be mild and transient: Common: Injection site reactions: redness, swelling, mild irritation at the injection location Headache: reported in some subjects, typically mild and temporary Mild gastrointestinal discomfort: occasional reports of nausea or upset stomach Less common: Temporary dizziness Slight increases in heart rate Minor liver enzyme elevations in some subjects These effects, when they occur, generally resolve without intervention and don't require discontinuation
intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
